Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review
- PMID: 35481701
- PMCID: PMC9773373
- DOI: 10.1093/abm/kaab119
Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review
Abstract
Background: People with human immunodeficiency virus (HIV) have an increased risk of cardiovascular disease (CVD) not fully accounted for by traditional or HIV-specific risk factors. Successful management of HIV does not eliminate this excess risk. Thus, there is a need to identify novel risk factors for CVD among people with HIV (PWH).
Purpose: Our objective was to systematically review the literature on one such candidate CVD risk factor in PWH-depression.
Methods: A systematic literature search of PubMed, PsycINFO, EMBASE, Web of Science, and CINAHL was performed to identify published English-language studies examining associations of depression with clinical CVD, subclinical CVD, and biological mechanisms (immune activation, systemic inflammation, altered coagulation) among PWH between the earliest date and June 22, 2021.
Results: Thirty-five articles were included. For clinical CVD (k = 8), findings suggests that depression is consistently associated with an increased risk of incident CVD. For subclinical CVD (k = 5), one longitudinal analysis reported a positive association, and four cross-sectional analyses reported null associations. For immune activation (k = 13), systemic inflammation (k = 17), and altered coagulation (k = 5), findings were mixed, and there was considerable heterogeneity in sample characteristics and methodological quality across studies.
Conclusions: Depression may be an independent risk factor for CVD among PWH. Additional research is needed to confirm depression's association with clinical CVD and to determine whether depression is consistently and meaningfully associated with subclinical CVD and biological mechanisms of CVD in HIV. We propose a research agenda for this emerging area.
Keywords: Cardiovascular disease; Coagulation; Depression; Human immunodeficiency virus; Immune activation; Systemic inflammation.
© Society of Behavioral Medicine 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
References
-
- Rodger AJ, Lodwick R, Schechter M, et al. ; INSIGHT SMART, ESPRIT Study Groups . Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27:973–979. - PubMed
-
- Palella FJ Jr, Baker RK, Moorman AC, et al. ; HIV Outpatient Study Investigators . Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
-
- Geovanini GR, Libby P. Atherosclerosis and inflammation: Overview and updates. Clin Sci (Lond). 2018;132:1243–1252. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical